Filing Flows

Filing Flows › Companies › Dianthus Therapeutics › Cash flow

Dianthus Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$50.7M in Q3 2026 · −$176M over twelve months

Operating cash flow−$50.3M
Capital spending−$368K
Free cash flow−$50.7M

Analysis

In Q3 2026, Dianthus Therapeutics generated −$50.3M of operating cash flow and spent $368K on capital projects, leaving free cash flow of −$50.7M. That is $20.1M less than in Q3 2025 (−$30.6M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$175M; the largest uses were other investing ($686M), operating cash flow ($175M), capital spending ($697K); besides operations, cash came from other financing ($833M), shares issued ($29.5M); the cash balance fell by $169K.

Operating cash flow was −$50.3M against net income of −$46.6M. The largest differences: stock-based pay +$12.7M, prepaid and other assets −$7.1M, receivables −$476K.

Free cash flow

Dianthus Therapeutics: free cash flow by quarterDianthus Therapeutics: free cash flow by quarter−$27.5MQ4 2024−$27.7MQ1 2025−$23.9MQ2 2025−$30.6MQ3 2025−$47.1MQ4 2025−$28.9MQ1 2026−$49.2MQ2 2026−$50.7MQ3 2026
Operating cash flow less capital spending.
Dianthus Therapeutics: operating cash flow against capital spendingDianthus Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$27.4M$31KQ4 2024−$27.6M$24KQ1 2025−$23.9M$46KQ2 2025−$30.6M$5KQ3 2025−$47.0M$138KQ4 2025−$28.9M$10KQ1 2026−$49.0M$181KQ2 2026−$50.3M$368KQ3 2026
Latest (Q3 2026): Operating cash flow −$50.3M, Capital spending $368K.

Capital allocation, year by year

Dianthus Therapeutics: where the cash came from (up) and went (down), by fiscal yearDianthus Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$9.9MFY2021: Shares issued $3.4MFY2021: Capital spending −$1.3M$3.4MFY2021FY2022: Operating cash flow −$29.1MFY2022: Shares issued $103MFY2022: Capital spending −$314K$103MFY2022FY2023: Operating cash flow −$36.9MFY2023: Shares issued $5KFY2023: Capital spending −$110K$5KFY2023FY2024: Operating cash flow −$78.2MFY2024: Shares issued $1.1MFY2024: Capital spending −$105K$1.1MFY2024FY2025: Operating cash flow −$129MFY2025: Shares issued $8.2MFY2025: Capital spending −$213K$8.2MFY2025
Over these 5 years operating cash flow totalled −$283M; the largest uses were operating cash flow ($283M) and capital spending ($2.0M). Cash-flow statements as filed.

Where the cash came from and went

Dianthus Therapeutics: sources (+) and uses (−) of cash, Q3 2026Dianthus Therapeutics: sources (+) and uses (−) of cash, Q3 2026Other investing−$112MOther financing$98.1MCash drawn (+) / kept (−)$54.7MOperating cash flow−$50.3MShares issued$9.4MCapital spending−$368K
Dianthus Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Dianthus Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$833MOther investing−$686MOperating cash flow−$175MShares issued$29.5MCapital spending−$697KCash drawn (+) / kept (−)$169K

From profit to cash

Dianthus Therapeutics: net income to operating cash flow, Q3 2026Dianthus Therapeutics: net income to operating cash flow, Q3 2026Net income−$46.6MDepreciation & amortization$37KStock-based pay$12.7MReceivables−$476KDeferred revenue−$430KPrepaid and other assets−$7.1MOperating cash flow−$50.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$50.3M−$368K$9.4M$54.7M−$50.7M
Q2 2026−$49.0M−$181K$10.6M$517M−$49.2M
Q1 2026−$28.9M−$10K$4.4M−$577M−$28.9M
Q4 2025−$47.0M−$138K$5.1M$4.9M−$47.1M
Q3 2025−$30.6M−$5K$2.4M−$42.7M−$30.6M
Q2 2025−$23.9M−$46K$568K−$3.1M−$23.9M
Q1 2025−$27.6M−$24K$160K$12.7M−$27.7M
Q4 2024−$27.4M−$31K$476K$10.9M−$27.5M

Dianthus Therapeutics: income statement and cash flow

Dianthus Therapeutics, Q4 2025: revenue $284K (-79% year over year). The chart follows the revenue to costs, profit and cash.

Dianthus Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.